Several other equities analysts have also recently weighed in on the stock. Baader Bank set a €19.00 ($22.62) target price on shares of MediGene and gave the company a buy rating in a research note on Thursday, November 9th. Oddo Securities set a €12.00 ($14.29) price objective on shares of MediGene and gave the company a buy rating in a research report on Tuesday, August 8th.
MediGene (ETR MDG1) traded up €0.03 ($0.04) during mid-day trading on Wednesday, hitting €11.77 ($14.01). 68,211 shares of the company’s stock were exchanged, compared to its average volume of 226,240. MediGene has a 12-month low of €8.40 ($10.00) and a 12-month high of €15.24 ($18.14).
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with MarketBeat.com's FREE daily email newsletter.